UVA biomedical engineering professor Kimberly Kelly founded ZielBio to bring new cancer treatments to market.
Science Serving Humanity
All too often, innovations in biomedical engineering that could significantly improve the healthcare of people around the world never enter the marketplace. The University of Virginia has joined forces with the Wallace H. Coulter Foundation in a groundbreaking effort to address the root causes of this bottleneck and commercialize promising treatments and techniques.
As one of just 16 universities nationwide selected as a Coulter Translational Partner in Biomedical Engineering, we are building out a new hands-on, high-touch ecosystem for translation even as we accelerate and broaden the flow of cutting-edge products, protocols and processes from University labs into clinical practice.
Our goal is to realize Wallace Coulter’s goal of “science serving humanity.” We invite you to join us.
Technology developed in the Papin Lab marks the first new technology in the plate reader market in decades.
What started as an incidental discovery in a chemistry lab has turned into a project to help drug makers and doctors better heal foot...
Featured nationwide in publications ranging from Science to NBC News to Plumbing Engineer, researchers at the University of Virginia...
More About Us
The mission of the UVA-Coulter Translational Partnership is to support research projects that are explicitly translational in nature and in the doing so, develop and validate models of translational that can be widely adopted.More
The insight and experience of our oversight committee is critical both to the success of the program and the progress of the individual projects we fund.More
Projects and Proposals
There are two paths to funding from the UVA-Coulter Partnership.More
$ 26 M
Coulter Program Endowment
$ 700 K
Invested in 6 - 8 projects per year
Projects funded over the last 12 years
$ 50 M
Follow-on funding from 17 Coulter-funded start-ups